Tsertsvadze Tengiz, Chkhartishvili Nikoloz, Sharvadze Lali, Dvali Natia, Chokoshvili Otar, Gabunia Pati, Abutidze Akaki, Nelson Kenrad, Dehovitz Jack, Del Rio Carlos
Infectious Diseases, AIDS and Clinical Immunology Research Center (IDACIRC), 16 Al. Kazbegi Avenue, Tbilisi 0160, Georgia.
AIDS Res Treat. 2011;2011:621078. doi: 10.1155/2011/621078. Epub 2011 Feb 21.
Since 2004, Georgia achieved universal access to free antiretroviral therapy (ART). A retrospective cohort study was conducted to evaluate the outcomes of Georgia's ART program. The study included adult patients enrolled in the ART program from 2004 through 2009. Of 752 patients, 76% were men, 60% were injection drug users (IDU), 59% had a history of an AIDS-defining illness, and 53% were coinfected with hepatitis C. The median baseline CD4 cell count was 141 cells/mm(3). During followup, 152 (20%) patients died, with the majority of deaths occurring within 12 months of ART initiation. Mortality was associated with advanced immunodeficiency or the presence of incurable disease at baseline. Among patients remaining on treatment, the median CD4 gain was 216 cell/mm(3) and 86% of patients had viral load <400 copies/ml at the last clinical visit. The Georgia ART program has been successful in treating injection drug users infected with HIV.
自2004年以来，格鲁吉亚实现了抗逆转录病毒疗法（ART）的全民免费普及。开展了一项回顾性队列研究以评估格鲁吉亚抗逆转录病毒疗法项目的成果。该研究纳入了2004年至2009年期间参加抗逆转录病毒疗法项目的成年患者。在752名患者中，76%为男性，60%为注射吸毒者（IDU），59%有艾滋病界定疾病史，53%合并感染丙型肝炎。基线CD4细胞计数中位数为141个细胞/mm³。在随访期间，152名（20%）患者死亡，大多数死亡发生在开始抗逆转录病毒疗法后的12个月内。死亡率与基线时的严重免疫缺陷或存在无法治愈的疾病有关。在继续接受治疗的患者中，CD4细胞计数增加的中位数为216个细胞/mm³，86%的患者在最后一次临床就诊时病毒载量<400拷贝/ml。格鲁吉亚的抗逆转录病毒疗法项目在治疗感染艾滋病毒的注射吸毒者方面取得了成功。
